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CD40 is a critical stimulatory receptor on antigen-presenting cells of the immune system
CD40-mediated activation of B cells is particularly important for normal humoral immun
function. Engagement of CD40 by its ligand, CD154, on the surface of activatedT cells ini
tiates a variety of signals in B cells including the activation of MAP kinases and NF-κB. Th
transcriptional regulator NF-κB is in reality a family of factors that can promote B cell activa
tion, differentiation, and proliferation. Complex – and only partially understood – biochemica
mechanisms allow CD40 to trigger two distinct NF-κB activation pathways resulting in th
activation of canonical (NF-κB1) and non-canonical (NF-κB2) NF-κB. This brief review pro
vides a summary of mechanisms responsible for activation of the latter, which appear
to be particularly important for enhancing the viability of B cells at various stages in thei
life cycle and may also contribute to the development of B cell malignancies. CD40 i
also expressed by various cell types in addition to B cells, including T cells, macrophages
dendritic cells, as well as certain non-hematopoietic cells. Here too, while perhaps les
extensively studied than in B cells, the CD40-mediated activation of NF-κB2 also appear
to have important roles in cellular physiology.
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The transcriptional regulator NF-κB participates in many impor-
tant activation events in B cells, including B cell proliferation and
differentiation in response to signaling by tumor necrosis factor
receptor (TNFR) family members or toll-like receptor (TLR) pro-
teins (1). NF-κB is not a single transcription factor, but rather
a family of factors composed of homo- and hetero-dimers of
p50, p52, c-Rel, RelA (p65), and RelB. Activation of these dimer
pairs occurs via two general mechanisms, sometimes referred to as
the canonical and non-canonical pathways. Canonical (NF-κB1)
activation is typically rapid as it does not usually require new pro-
tein synthesis. Activation of this pathway is mediated largely by
degradation of inhibitors present in the cytoplasm, which allows
transit of NF-κB dimers (typically p50/RelA or p50/c-Rel hetero-
dimers) into the nucleus. In contrast, activation of non-canonical
NF-κB (NF-κB2) often occurs after activation of the canonical
pathway, may require new protein synthesis, and ultimately results
in the nuclear localization of predominantly p52/RelB hetero-
dimers, although p52/p65 and p52/c-Rel hetero-dimers have also
been described (2). Excellent recent reviews discuss current gen-
eral models of NF-κB2 activation (2–5). Briefly, the activation of
the NF-κB2 pathway is largely regulated by the production and
posttranslational processing of its precursor, p100. Its proteolytic
processing is regulated by IκB kinase α (IKKα), which is in turn
regulated by NF-κB-inducing kinase (NIK).
CD40-MEDIATED NF-κB2 ACTIVATION IN B CELLS
CD40 signaling in B cells can modulate the activation of NF-κB2
at several points. First, CD40 signaling strongly activates NF-κB1
in B cells. This activation leads to the enhanced production of
p100 (4). In addition, CD40 can regulate the posttranslational
processing of p100 by regulating the activity of NIK (6). In resting
cells, NIK activity is inhibited by a protein complex that includes
TNFR-associated factor (TRAF)2, TRAF3, and cellular inhibitors
of apoptosis (cIAP)1/2 (5). The major function of this complex
appears to be in mediating the ubiquitination and degradation of
NIK in resting B cells. Within the complex,TRAF3 appears to inter-
act with NIK, while TRAF2 mediates interactions between TRAF3
and the cIAP molecules. Engagement of CD40 by its ligand leads
to recruitment of TRAF proteins, including TRAFs 2 and 3, to the
cytoplasmic domain of CD40. This event disrupts the NIK regu-
latory function of the TRAF2/TRAF3/cIAP complex, perhaps by
promoting the ubiquitination, and degradation of TRAF3. With
disruption of the NIK regulatory complex, NIK begins to accumu-
late (via new protein synthesis) in the cytoplasm to levels where
it promotes the phosphorylation and activation of IKKα. In turn,
IKKα activity mediates the phosphorylation of p100, which tar-
gets the protein for processing by the proteasome, resulting in p52
production (3–5).
A number of genetically modified mouse strains and cell lines
have contributed to our understanding of NF-κB2 regulation by
CD40 in B cells (7–11). TRAF2, TRAF3, and TRAF6 all signifi-
cantly contribute to this CD40 signal transduction. Mouse B cell
lines deficient in TRAF2 or TRAF6 exhibit little or no defect in
CD40-mediated NF-κB2 activation (10). However, B cell lines
doubly deficient in TRAF2 and TRAF6 appear defective in the
activation of NF-κB2, suggesting that the two molecules have
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overlapping functions in the activation of this pathway. Potentially,
these results are explained by the ability of CD40, through TRAF2
and TRAF6, to activate the NF-κB1 pathway, which in turn acti-
vates p100 transcription. Primary B cells from TRAF2-deficient
mice exhibit elevated basal NF-κB2 activation (not observed in
the cell line studies), which is only weakly augmented by CD40
signaling (9), consistent with a role for TRAF2 in the NIK reg-
ulatory complex. In the cell line studies, TRAF2 deficiency did
not appear to augment the basal level of p52 production (10),
although this may have been due to limited production of p100
in non-activated cells. B cells from mice conditionally deficient
in TRAF3 specifically in B cells also exhibit strong constitutive
activation of the NF-κB2 pathway (7, 11), which is again consis-
tent with the model in which TRAF3 is a major component of
the NIK regulatory complex. While the phenotypes of TRAF2-,
cIAP-, and TRAF3-deficient primary B cells are somewhat sim-
ilar with respect to the constitutive activation of NF-κB2, there
are instructive differences between the strains [reviewed in (5)].
CD40-mediated differentiation of B cells into germinal center B
cells is augmented in TRAF3-deficient mice (7, 11), but TRAF2-
or cIAP-deficient mice have a significant defect in germinal center
B cell development (8). This likely reflects the role of TRAF2/cIAP
in activation of the NF-κB1 pathway, which TRAF3 does not
share.
Interestingly, in B cell-specific TRAF3-deficient mice, the ele-
vated constitutive activation of NF-κB2 can be enhanced some-
what by CD40 stimulation (11), indicating the existence of TRAF3-
independent mechanisms of NIK/NF-κB2 regulation. This possi-
bility is further supported by the observation that CD40 signaling
can activate NF-κB2 in TRAF3-deficient B cell lines reconstituted
with a mutant TRAF3 molecule that binds NIK robustly, but is
not degraded following CD40 stimulation (Lin et al., this issue).
These observations demonstrate that the regulation of NF-κB2 by
CD40 in B cells is only partially understood. Recently, the protein
kinase TANK-binding kinase 1 (TBK1) was shown to negatively
regulate NF-κB2 activation and IgA Ig isotype switching in pri-
mary B cells, potentially through phosphorylation/degradation of
NIK (12). The de-ubiquitinating enzyme OTUD7B was also shown
recently to potentially negatively regulate NF-κB2 (and primary B
cell activation) by inhibiting activation-induced degradation of
TRAF3 (13). Additionally, zinc finger protein 91 has recently been
shown to promote NIK stability in a CD40-stimulated epithelial
tumor cell line, perhaps through K63-linked polyubiquitination
of NIK (14). Whether this mechanism is relevant to the CD40-
mediated activation of B cells remains to be demonstrated. It is
likely that additional regulatory mechanisms will come to light
in the next few years, and will contribute to our understand-
ing of normal B cell biology as well as the physiology of B cell
malignancies.
CD40-MEDIATED NF-κB2 ACTIVATION IN NON-B CELLS
Compared to the extensive research performed in B cells, a cell
type in which NF-κB activation is a major regulatory pathway, rel-
atively little investigation has been performed on CD40-mediated
NF-κB2 signaling in other cell types. Most studies of CD40 func-
tions in non-B cells do not examine NF-kB activation. In those
that do, canonical NF-κB1 activation is typically the focus, and/or
methods used (reporter gene activation or electrophoretic mobil-
ity shift assay, EMSA) do not allow results to distinguish between
NF-κB1 and NF-κB2 induction. We summarize below the infor-
mation that is currently available on CD40-mediated induction of
the NF-κB2 pathway in non-B cells.
OTHER HEMATOPOIETIC CELLS
T lymphocytes
The physiologic importance of direct signaling to T cells by CD40
has at times been a controversial topic (15). However, there is no
doubt that normal activated CD4+ and CD8+ T cells can express
CD40, and it appears to play significant biological roles in mouse
models of T cell-dependent immune responses (16, 17), including
autoimmune responses [reviewed in Ref. (15)]. However, the role
of CD40-mediated NF-κB activation, and in particular NF-κB2
activation in these roles is unclear, and may be context-dependent.
CD3+CD8+CD40+ T cells in Balb/c mice exhibit cytotoxic activity
toward CD4+CD25+ T regulatory cells during Leishmania infec-
tion – this activity is CD40-dependent,but unaffected by inhibitors
of NF-κB (18). A CD4+ mouse T cell line stably expressing trans-
fected CD40 utilizes CD40 as an effective co-stimulatory signal
with T cell receptor signals to activate T cell functions. In this
model, both NF-κB1 and NF-κB2 pathways in T cells are activated
by CD40 (19). The ultimate biological importance of NF-κB2
activation in T cell CD40 signaling remains to be explored.
Myeloid cells
Monocytes and macrophages, like B cells, constitutively express
CD40, which activates mitogen-activated protein (MAP) kinases
and NF-κB in these cells [reviewed in Ref. (20)]. However, very
little is known about the potential involvement of the NF-κB2
pathway in macrophage CD40 signaling. Revy et al. performed a
direct comparison between human monocytes and B cells acti-
vated through CD40. EMSA demonstrated that nuclear translo-
cation of NF-κB binding activity is induced by CD40 in both cell
types, and the p50 subunit involved in NF-κB1 activation is part
of these nuclear complexes. Interestingly, the p65 subunit was only
present in complexes from B cells (21). However, as the CD40 stim-
ulation was only of short duration in these experiments (30 min);
the activation of NF-κB2 was not assessed at later times.
CD40 also delivers potent and important signals to dendritic
cells (DC) [reviewed in Ref. (22)]. Following signals from CD40
that stimulate the ability of DC to cross-present antigen to T cells,
the nuclear translocation of p52 characteristic of NF-κB2 signaling
is seen. Mice bearing a mutant NIK that disrupts NF-κB2 activa-
tion by various signals, the NIKaly/aly mouse, show DC functional
defects (23). CD40 fails to induce cross presentation of antigens
to CD8 T cells in the NIKaly/aly mouse, implicating NF-kB2 in this
particular DC function. However, the evidence is indirect, as the
NIK mutation is expressed in all cells of the mouse, and will impact
multiple pathways of cell development and function. In another
experimental model, human monocyte-derived DC treated with
siRNA for NIK or IKKα are unable to produce the cytokines IDO
and IL-6 following in vitro stimulation with the CD40 ligand,
CD154. This also renders the treated DC unable to promote the
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induction of T regulatory cells (24). Thus, NF-κB2 signaling plays
important roles in CD40 functions in DC.
NON-HEMATOPOIETIC CELLS
Epithelial cells
CD40 was first described as an antigen expressed on the surface of
bladder carcinoma cells (25), and can be expressed on a variety of
types of epithelial cells under particular circumstances [reviewed
in (26, Lin et al., this issue)]. Unfortunately, by far the most com-
monly used cells of epithelial origin used to study CD40 signaling
are the transformed cell lines HEK 293 and HeLa. In the majority
of studies using these cell lines, CD40 and/or the signaling pro-
teins studied are exogenously expressed at highly non-physiologic
levels. Thus, because such models can provide misleading results
[recently reviewed in (27)], we will not discuss this body of work
in this article. Very little is known about the usage of the NF-κB2
pathway by endogenous CD40 expressed by normal epithelial cells.
An interesting report using airway epithelial cells, which produce
the cytokine RANTES upon CD40 stimulation, examined NF-κB
activation by EMSA. Nuclear binding complexes for probes with
sites characteristic of both NF-κB1 and NF-κB2 were identified,
with the former peaking at 30 min of stimulation, and the latter at
2 h. The p65 subunit was present in both types of complexes (28).
The functional importance of this NF-κB2 activation remains to
be defined.
Fibroblasts
Although CD40 can be expressed by fibroblasts, no information
is currently available on the extent or importance of NF-κB2
activation by CD40 in this cell type. A recent report made the
interesting observation that TWEAK, a molecule implicated in
various fibrotic processes [reviewed in (29)] inhibits CD40 sig-
naling in the HeLa cell line (30). However, neither fibroblasts nor
NF-κB2 pathways were examined in this study.
Vascular endothelium
It is well-known that CD40 can be expressed on activated endothe-
lium, and its interaction with CD154 has been implicated in the
pathogenesis of atherosclerosis [reviewed in Ref. (31)]. A specific
role for NF-κB2 activation has yet to be explored in this CD40
function. In human vascular endothelial cells, stimulation of CD40
with soluble CD154 stimulates the phosphorylation and nuclear
translocation of the p65 subunit of NF-κB at 6 h (32). However, it is
unclear whether this represents activation of the NF-κB2 pathway.
While it is clear that the mechanisms of CD40-mediated NF-κB
activation are complicated (and still incompletely characterized),
the consequences of NF-κB activation in B cells and other cells are
orders of magnitude more complex. Many of the genes regulated
by NF-κB have been identified by experiment and by computer
analysis, but the work of understanding the subsequent roles of
these genes and their interactions in cellular physiology is only
in its infancy. Nevertheless, continued characterization of NF-
κB activation mechanisms and consequences of NF-κB-regulated
transcription will lead to a more complete understanding of basic
immune system biology as well as the identification of molecular
events and interactions that can be exploited in the treatment of
immune disorders and cancer.
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